In laboratory experiments, Canadian researchers found that isolated compounds in cranberries, called flavonoids, may inhibit the growth of breast cancer cells when consumed in sufficient concentrations. These naturally-occurring flavonoids may also help prevent other forms of cancer, including those of the prostate, colon, lungs and brain.
The study, led by Peter Ferguson of the University of Western Ontario and the London Regional Cancer Program, suggests that the cranberry's flavonoids may block the further spread of estrogen-dependent breast cancer cells and cause the existing ones to die. In Dr Ferguson's study, a cranberry extract (containing 250mg of flavonoids per liter) inhibited breast cancer cell proliferation 50%, the USA Cranberry Institute has reported.
The researchers conclude, in their recent article published in the Journal of Nutrition, that cranberry may be a novel anticancer agent. This has particular relevance given concern surrounding recurrence of drug-resistant tumors. The study received funding from the American Institute for Cancer Research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze